LAURA BOUNDS: Open Payments
NPI 1750988101 · CHARLES CITY, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,548 in 69 payments from 19 companies in 2025. Trend: 2023 $248 · 2024 $772 · 2025 $1,548
Food & beverage: $1,548
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $391 |
| Lilly USA, LLC | 9 | $250 |
| Amgen Inc. | 5 | $174 |
| Novo Nordisk Inc | 7 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| PFIZER INC. | 5 | $93 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $55 |
| Merck Sharp & Dohme LLC | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $44 |
Products named: QULIPTA, UBRELVY, REPATHA, MOUNJARO, ZEPBOUND, CAPLYTA, JARDIANCE, ELIQUIS.
Industry payments across VA — which companies pay providers there.
